Lantheus stock reacts to Curium takeover deal and insider moves
Published on 09/03/2026 at 12:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lantheus Holdings, Inc. stock (ISIN US5156731020) is trading close to the 100 dollar mark as of September 2, 2026, with investors weighing a pending cash takeover by Curium alongside fresh insider activity around the shares.
Curium’s cash offer sets valuation frame
According to data compiled by MarketBeat, Curium has agreed to buy Lantheus in a deal that values the company at up to 114.50 dollars per share in cash, announced on August 3, 2026.
The agreed consideration of up to 114.50 dollars per share comes against a recent closing price of 100.81 dollars for Lantheus stock on September 2, 2026, implying a takeover premium of around 13.6 percent relative to that latest close.
Insider transactions around the 100 dollar level
Insider share movements have added another layer to the story. As reported by Stock Titan’s summary of a recent Form 4 filing, Lantheus Chief Financial Officer and Treasurer Robert J. Marshall Jr. disposed of 721 shares of common stock on August 31, 2026, at a reported price of 100.96 dollars per share to cover an option exercise price or tax obligations.
Following that August 31, 2026 transaction at 100.96 dollars per share, the CFO directly holds 122,071 Lantheus shares, illustrating how management’s exposure remains substantial even after using a small portion of stock for exercise and tax payments.
Separate market data compiled by MarketBeat on institutional activity shows Lantheus stock opening at 100.88 dollars in recent trading, close to both the CFO’s reported sale level and the broader market’s view of fair value ahead of the Curium deal.
Analyst view and price targets
Analyst consensus has stabilized around the current price region. According to the same MarketBeat overview, Lantheus shares carry a consensus Hold rating from research houses, with an average price target of 108.11 dollars per share based on recent analyst reports.
That 108.11 dollar average target sits between the latest trading zone around 100.81 dollars as of September 2, 2026 and the maximum Curium consideration of up to 114.50 dollars, suggesting that the agreed deal terms are broadly in line with analyst expectations while still reflecting an additional upside relative to the most recent close.
Within the consensus, individual targets such as a 102.50 dollar price objective set by William Blair in early August 2026 highlight how some analysts see limited upside from current levels, while others implicitly endorse the higher takeover valuation embedded in Curium’s offer.
Product and business focus in precision imaging
Lantheus is best known for its diagnostic imaging agents and radiopharmaceuticals used in cardiovascular and oncology applications, which underpin the company’s appeal in a consolidating sector where scale and pipeline breadth matter.
For investors, the strategic rationale behind Curium’s plan to acquire Lantheus rests on combining Lantheus’ established imaging portfolio with Curium’s broader nuclear medicine platform, potentially strengthening the positioning of key products in markets such as the United States and Europe.
Lantheus stock price context
Lantheus stock last closed at 100.81 dollars on September 2, 2026 on the Nasdaq, with an opening level of 100.88 dollars reported in the same period, positioning the shares below the agreed cash consideration ceiling of 114.50 dollars but above the 102.50 dollar individual analyst target mentioned in recent research.
Lantheus stock at a glance
- Company: Lantheus Holdings, Inc.
- ISIN: US5156731020
- Ticker: LNTH
- Trading venue: Nasdaq
- Price (as of September 2, 2026): 100.81 USD
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 400 Midcap
